Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Maroof Hasan"'
Autor:
Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan
Publikováno v:
Blood. 140:732-734
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6e18f6152aae6e3b2d76f43c90627ab
https://doi.org/10.1182/blood-2022-158967
https://doi.org/10.1182/blood-2022-158967
Autor:
Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Publikováno v:
Scientia
Enasidenib; Conventional care Enasidenib; Atenció convencional Enasidenib; Atención convencional This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3715a5d50e378580e2588f9f261b90de
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
Autor:
Douglas RA RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Sarah Mackie, Roan Hulks, Olena Yavorska, Paulina Siejka-Zielinska, Marlen Metzner, Alastair Smith, Batchimeg Usukhbayar, Virginie Penard-Lacronique, Chunxiao Song, Anita K. Gandhi, Maroof Hasan, Paresh Vyas, Thomas A. Milne, Skirmantas Kriaucionis, Lynn Quek
Publikováno v:
Blood. 140:8698-8699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc464d95e14bd0f3c3dc7f6c6826c550
https://doi.org/10.1182/blood-2022-165898
https://doi.org/10.1182/blood-2022-165898
Autor:
Prodromos Chatzikyriakou, Douglas RA Silveira, Maria del Pilar Casares Aláez, Batchimeg Usukhbayar, Marlen Metzner, Paresh Vyas, Anita K. Gandhi, Alberto Risueño, Maroof Hasan, Lynn Quek
Publikováno v:
Blood. 140:3414-3415
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4a2f3b5eaa060a479f3acb817902555
https://doi.org/10.1182/blood-2022-163717
https://doi.org/10.1182/blood-2022-163717
Autor:
Courtney D. DiNardo, Stéphane de Botton, Alberto Risueño, Andre C. Schuh, Bob Löwenberg, Hee-Je Kim, Paresh Vyas, Andrew H. Wei, Eytan M. Stein, Hartmut Döhner, Amir T. Fathi, Patricia Martin-Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L. See, Maroof Hasan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S249-S250
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::378f36a9d79a8130bc59e00dcb3445a6
https://doi.org/10.1016/s2152-2650(22)01293-9
https://doi.org/10.1016/s2152-2650(22)01293-9
Autor:
Stéphane, de Botton, Pau, Montesinos, Andre, Schuh, Cristina, Papayannidis, Paresh, Vyas, Andrew H, Wei, Hans Beier, Ommen, Sergey, Semochkin, Hee-Je, Kim, Richard A, Larson, Jamie, Koprivnikar, Olga, Frankfurt, Felicitas R, Thol, Jörg, Chromik, Jenny L, Byrne, Arnaud, Pigneux, Xavier, Thomas, Olga, Salamero, María-Belén, Vidriales, Vadim A, Doronin, Hartmut, Döhner, Amir T, Fathi, Eric, Laille, Xin, Yu, Maroof, Hasan, Patricia, Martín-Regueira, Courtney D, DiNardo
Publikováno v:
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 inhibitor, with conventional care regimens (CCR) in patients aged =60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f5721a519b6f1e60c6aafec14ec22139
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
Autor:
Courtney D. DiNardo, Stéphane de Botton, Alberto Risueño, Andre C. Schuh, Bob Löwenberg, Hee-Je Kim, Paresh Vyas, Andrew H. Wei, Eytan M. Stein, Hartmut Döhner, Amir T. Fathi, Patricia Martin-Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L. See, Maroof Hasan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S124
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e35ac64b73fcf03b3730bec43724ae1
https://doi.org/10.1016/s2152-2650(22)00742-x
https://doi.org/10.1016/s2152-2650(22)00742-x
Autor:
Courtney Dinardo, Jing Gong, Paresh Vyas, Amer M. Zeidan, Eytan M. Stein, Patricia Martin-Regueira, Stéphane de Botton, Pau Montesinos, Maroof Hasan, Amir T. Fathi, John M. Bennett, Andrew H. Wei, Frederik Lersch, Mark G. Frattini, Hagop M. Kantarjian, Hartmut Döhner, Andre C. Schuh
Publikováno v:
The Lancet. Oncology. 22(11)
Background: Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e030ee08cc9805beae386d6189a6a742
https://pubmed.ncbi.nlm.nih.gov/34672961
https://pubmed.ncbi.nlm.nih.gov/34672961
Autor:
Stéphane De Botton, Alberto Risueño, Andre C. Schuh, Bob Lowenberg, Hee-Je Kim, Paresh Vyas, Andrew H. Wei, Eytan M. Stein, Hartmut Dohner, Amir Tahmasb Fathi, Courtney Denton Dinardo, Patricia Martin Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L. See, Maroof Hasan
Publikováno v:
Journal of Clinical Oncology. 40:7005-7005
7005 Background: IDH2 gene mutations (m IDH2) occur in up to ̃20% of patients (pts) with acute myeloid leukemia (AML), most commonly as R140Q (in ̃75% of cases) or R172K (̃25%) point mutations. The functional effects and prognostic relevance of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c92427eb6dc71bae489c9e722147c1e7
https://doi.org/10.1200/jco.2022.40.16_suppl.7005
https://doi.org/10.1200/jco.2022.40.16_suppl.7005
Autor:
Amanda Littlewood-Evans, Joschka Willemsen, Thomas Hoyler, Marie-Therese Neuhoff, Clemence Tessier, Juan Zhang, Tara N. Thorsen, Maroof Hasan, Sophie Sarret, James S. Rush, Richard M. Siegel, Emma Noir, Danilo Guerini
Publikováno v:
Cell reports. 37(6)
Tumor necrosis factor (TNF) is a key driver of several inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, in which affected tissues show an interferon-stimulated gene signature. Here, we demonstrate that T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f390fc90121d892f5efbd86eac953e
https://pubmed.ncbi.nlm.nih.gov/34758308
https://pubmed.ncbi.nlm.nih.gov/34758308